{"id":"W2605337228","doi":"10.1200/jco.2014.32.15_suppl.5519","title":"A phase II randomized open-label study of MM-121, a fully human monoclonal antibody targeting ErbB3, in combination with weekly paclitaxel versus weekly paclitaxel in patients with platinum-resistant/refractory ovarian cancers.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"ca_institutions":"Juravinski Cancer Centre","funders":"","keywords":"Paclitaxel; Medicine; Hazard ratio; Internal medicine; Ovarian cancer; Progression-free survival; Monoclonal antibody; Oncology; Refractory (planetary science); Chemotherapy; Gastroenterology; Cancer; Urology; Confidence interval; Antibody; Immunology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002727594,0.002322958,0.003335285,0.0007790342,0.0004555447,0.001138512,0.001209135,0.001739215,0.005750459],"category_scores_gemma":[0.00194298,0.0009337722,0.001549636,0.0006261604,0.001916442,0.001568302,0.0006256,0.003394281,0.0009901046],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0010677,"about_ca_system_score_gemma":0.001562901,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007253481,"about_ca_topic_score_gemma":0.001734174,"domain_scores_codex":[0.9989963,0.0006194956,0.00003802952,0.0001494319,0.00006231243,0.0001344328],"domain_scores_gemma":[0.9985336,0.00036546,0.0003317426,0.0001219771,0.00007094898,0.0005762961],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9622521,0.02075133,0.001020272,0.0002227524,0.0003913967,0.00003586026,0.00005388507,0.0004291692,0.003821999,0.00009399228,0.0005638091,0.01036347],"study_design_scores_gemma":[0.838459,0.1584109,0.001617207,0.000009064168,0.0001636567,0.0000303163,0.0000212498,0.0003819125,0.0004131999,0.0001074775,0.0003752102,0.00001099563],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9845905,0.001583348,0.001039624,0.0006347781,0.0003633365,0.008612577,0.001372303,0.0001351499,0.001668292],"genre_scores_gemma":[0.9799924,0.001292039,0.002375538,0.001287649,0.000548229,0.01000846,0.001566799,0.00004146486,0.002887262],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005750459,"threshold_uncertainty_score":0.01923716,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07753090838274025,"score_gpt":0.4464672778584613,"score_spread":0.3689363694757211,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}